Brilacidin

What is Brilacidin?

Brilacidin is a synthetic small molecule designed to reproduce the biological behaviour of host-defence peptides without being one. It belongs to a chemical class called arylamide foldamers: non-natural oligomers whose backbone folds into a predictable shape, here an amphipathic arrangement with cationic groups on one face and hydrophobic groups on the other — the same architecture that makes natural defensins membrane-active. Its formula is C40H50F6N14O6 with a molecular weight of about 937 (PubChem CID 25023695), and it contains no amino acids and no peptide bonds. This matters for how the molecule should be understood and for why it is on a peptide reference at all. Brilacidin is routinely described in the literature as a defensin mimetic or host defence peptide mimetic, and one 2024 paper in Antibiotics is titled simply Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule. The design logic was explicitly to escape the drawbacks of real peptides — proteolytic degradation, manufacturing cost, poor oral properties — while keeping the mechanism. It is included here because it is consistently discussed as part of the antimicrobial peptide field, and because people searching for it deserve to be told plainly that it is a peptidomimetic rather than a peptide. It has been investigated across an unusually wide range of indications: intravenously for acute bacterial skin and skin structure infections, as an oral rinse for radiation-induced oral mucositis in head and neck cancer, as a delayed-release tablet for ulcerative colitis and inflammatory bowel disease, and intravenously for hospitalised COVID-19. None has reached Phase 3. Brilacidin has never been approved by any regulator for any indication, and no brilacidin trial is currently registered as active or recruiting.

What Brilacidin Is Investigated For

Brilacidin has been tested in more directions than most compounds of its stage, and the results are worth separating carefully because the loudest claims rest on the weakest data. The antibacterial programme is the oldest. A Phase 2 trial in acute bacterial skin and skin structure infections (NCT02052388) randomised 215 patients, double-blind, across three brilacidin regimens — a single 0.6 mg/kg intravenous dose, a single 0.8 mg/kg dose, and a three-day regimen — against standard seven-day daptomycin, with early clinical response as the primary endpoint. The company reported comparable response rates. Detailed results have never been posted to the trial registry or published in a peer-reviewed journal, so this remains a company-characterised result rather than an independently verifiable one. The oral mucositis trial (NCT02324335) enrolled 61 head and neck cancer patients receiving chemoradiation, randomised to brilacidin oral rinse at 3 mg/mL or a water placebo three times daily for seven weeks. Results are posted. In the prespecified analysis group receiving a cumulative radiation dose of at least 55 Gy, severe oral mucositis occurred in 15 of 25 placebo patients (60 percent) versus 9 of 21 on brilacidin (42.9 percent). That is a modest numerical difference in a small subset, with no p-value posted — suggestive, not conclusive. The COVID-19 trial is the clearest result in the programme, and it is negative. NCT04784897 enrolled 120 hospitalised patients and posted its results. Median time to sustained recovery through day 29 was 12 days on placebo, 13 days on the three-dose brilacidin regimen and 13 days on the five-dose regimen, with hazard ratios of 0.93 (95 percent CI 0.66 to 1.31, p=0.73) and 0.90 (0.55 to 1.47, p=0.60). The drug did not work for this indication. The most interesting current work is antifungal, and it is laboratory science rather than clinical. A 2023 paper in Nature Communications found brilacidin synergises with caspofungin against caspofungin-sensitive and caspofungin-resistant Aspergillus fumigatus, Candida albicans and Candida auris — and, strikingly, against Cryptococcus neoformans, which is intrinsically resistant to echinocandins. In an immunosuppressed mouse model of invasive pulmonary aspergillosis, the combination significantly cleared lung infection; brilacidin alone reduced fungal burden and prevented disease in a fungal keratitis model.

History & Discovery

Brilacidin came out of a specific academic programme in biomimetic chemistry. Through the late 1990s and 2000s, work at the University of Pennsylvania and elsewhere established that the antimicrobial activity of defensins did not require any particular sequence — it required a facially amphipathic arrangement of cationic and hydrophobic groups. If that was true, the activity ought to be reproducible in non-peptide scaffolds, which would escape the three practical problems that have kept natural antimicrobial peptides out of the clinic: rapid proteolytic degradation, expensive synthesis, and poor pharmaceutical properties. Arylamide foldamers, whose aromatic amide backbones adopt predictable folded conformations, proved to be a workable scaffold. PolyMedix, incorporated in 2002, was founded to commercialise this chemistry — the PMX prefix in PMX-30063 is the company's. It carried brilacidin into a Phase 2a trial before filing for Chapter 7 bankruptcy on 1 April 2013. Cellceutix acquired the PolyMedix assets through a stalking-horse bid approved by the United States Bankruptcy Court for the District of Delaware on 4 September 2013, for cash plus stock and assuming none of the company's debt. Cellceutix renamed itself Innovation Pharmaceuticals on 7 June 2017. The programme under its new ownership expanded rather than focused. The 215-patient skin infection trial against daptomycin completed in 2014. The oral mucositis rinse trial ran from 2014 to 2017. A colonic delayed-release tablet for ulcerative colitis was characterised in healthy volunteers in 2020. When COVID-19 arrived, cell-culture work showing activity against SARS-CoV-2 led to a Phase 2 trial in hospitalised patients that completed in July 2021 and failed its primary endpoint. What has kept brilacidin alive scientifically since then is work by independent academic groups rather than by its owner. From 2023 onward, laboratories studying fungal pathogens — particularly Gustavo Goldman's group and collaborators — have published a sustained series of papers on brilacidin's antifungal activity and its synergy with caspofungin and ibrexafungerp, including a 2023 paper in Nature Communications and a commentary in Nature Reviews Microbiology. That is an unusual trajectory: a clinical-stage compound whose most interesting results arrived years after its clinical programme stalled, from people who did not own it.

How It Works

Defensins are short peptides the immune system makes to kill microbes. They work because of their shape and charge: positively charged on one side, greasy on the other, which lets them stick to the negatively charged surface of a bacterial membrane and tear it apart. Brilacidin was built from scratch, out of completely different chemistry, to fold into that same shape and carry that same charge pattern. It does what a defensin does without being one — and because it is not made of amino acids, the enzymes that would chew up a real peptide cannot touch it.

Brilacidin is an arylamide foldamer. Its backbone is built from aromatic amide units whose rotational preferences force the molecule into a defined, extended conformation, with cationic side chains segregated on one face and hydrophobic groups on the other. This reproduces the facially amphipathic architecture of natural defensins and cathelicidins, which is the structural feature responsible for their selective interaction with microbial membranes — microbial membranes present more anionic lipid on their outer surface than mammalian ones, so a cationic amphipath partitions into them preferentially. The antibacterial mechanism has been studied directly rather than assumed. In Staphylococcus aureus, brilacidin causes membrane depolarisation comparable in magnitude to that caused by daptomycin. Deep-sequencing transcriptional profiling showed the global bacterial response to brilacidin correlates well with the responses to both daptomycin and LL-37, and indicates abrogation of cell wall and membrane functions. A less obvious component emerged from the same work: brilacidin and daptomycin both upregulate chaperones and proteases, which suggests cytoplasmic protein misfolding stress contributes to killing beyond simple membrane permeabilisation. The responses were coordinated by the GraSR, VraSR and NsaSR two-component systems, all previously implicated in virulence and resistance. The antifungal mechanism is distinct and more interesting. In Aspergillus fumigatus, brilacidin acts by affecting the cell wall integrity pathway and cell membrane potential. Because echinocandins such as caspofungin work by inhibiting beta-1,3-glucan synthesis — a cell wall target whose efficacy depends on the fungus being unable to compensate through the cell wall integrity pathway — a molecule that simultaneously disrupts that compensatory signalling turns a fungistatic or ineffective drug into an effective one. That is the proposed basis for the synergy observed against caspofungin-resistant isolates and against Cryptococcus neoformans, which is intrinsically echinocandin-resistant. Mechanistic work published in 2026 using lipid membrane models and transcriptional profiling of Cryptococcus has begun to map this in more detail. The antiviral activity reported against SARS-CoV-2 appears to be mechanistically different again: work in Calu-3 and Vero cells attributed inhibition to effects on viral entry and disruption of viral integrity, with synergy against remdesivir. Enveloped viruses have lipid membranes, so a membrane-active amphipath having some effect on them in culture is unsurprising — and the clinical trial showed this did not translate.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Brilacidin:

• 01Does the skin infection result exist? The 215-patient Phase 2 trial against daptomycin is the most-cited efficacy claim for brilacidin, and its results have never been posted to the registry or published in a peer-reviewed journal. More than a decade after completion, that absence is itself informative, and it means the central antibacterial claim cannot be independently assessed.
• 02Can the antifungal synergy be achieved at tolerable human exposures? The caspofungin potentiation is the most compelling data in the brilacidin literature, but it exists only in vitro and in mice. Nobody has established what plasma or tissue concentration of brilacidin is needed, or whether that is reachable given what is known about its tolerability.
• 03Why did potent cell-culture antiviral activity produce no clinical effect in COVID-19? The gap between striking in vitro potency, including synergy with remdesivir, and a hazard ratio of 0.93 for time to recovery is worth understanding rather than dismissing, because the same pattern will recur with other membrane-active antivirals.
• 04What is brilacidin's systemic pharmacokinetic profile? Absorption, distribution, metabolism, excretion and tissue accumulation of a polycationic arylamide foldamer are not described in the accessible literature, and a 200 mg oral delayed-release tablet study in nine volunteers measured where the radiolabel went rather than what the drug did.
• 05Does resistance develop, and at what cost? For a membrane-active mimetic the expectation is that resistance is slow and costly, since it would require remodelling the membrane surface charge — but this has not been systematically tested over serial passage for brilacidin in the way it has for murepavadin.
• 06Is the mucositis signal real? Severe oral mucositis occurred in 60 percent of placebo and 42.9 percent of brilacidin patients in the prespecified high-radiation-dose subset, with no p-value posted and 46 evaluable patients. Oral mucositis is a large unmet need with few options, and a properly powered trial would settle a question that a 61-patient study cannot.
• 07Will anyone develop it? The compound has had no new registered trial since 2021 and has been listed as available for licensing, while independent academic groups continue to publish interesting findings about it. Whether the antifungal work attracts a developer is a commercial question that determines whether any of the above gets answered.

Forms & Administration

Brilacidin has been formulated three ways across its clinical history. Intravenous infusion was used for acute bacterial skin and skin structure infections — single doses of 0.6 or 0.8 mg/kg, or 0.6 mg/kg on day 1 followed by 0.3 mg/kg on days 2 and 3 — and for the COVID-19 trial. An oral rinse at 3 mg/mL in water for injection, used three times daily, was studied for radiation-induced oral mucositis. A delayed-release tablet designed for colonic delivery was studied in nine healthy volunteers at 50, 100 and 200 mg, using scintigraphic imaging of a radiolabel to confirm the site and timing of release in the colon, for the inflammatory bowel disease programme. The oral tablet deserves note as a design choice rather than a convenience. Brilacidin is polycationic and poorly absorbed, which would be a liability for a systemic drug but is an advantage for ulcerative colitis, where the goal is high local concentration at the colonic mucosa with minimal systemic exposure. The Phase 1 study existed to confirm that the tablet actually released where it was supposed to. There is no approved product and no legitimate supply. Brilacidin is available to researchers as a laboratory chemical, which is how the antifungal and antiviral work has been done, and that is its only current legitimate use.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Brilacidin is an unapproved investigational compound that has not progressed beyond Phase 2 in any indication, has no registered active clinical trial, and has no legitimate commercial supply for human use. Material sold under this name is a research chemical of unverified identity and purity.

Timeline of Effects

Common Questions

Who Brilacidin Is NOT For

Drug & Supplement Interactions

No formal human drug interaction studies of brilacidin have been published, and its systemic pharmacokinetics are poorly characterised in the public literature. As a non-peptide small molecule it is not subject to peptidase degradation, but whether it is a substrate, inhibitor or inducer of cytochrome P450 enzymes or drug transporters does not appear to have been reported. The interactions that have actually been studied are deliberate combinations, and they are the most interesting part of the brilacidin literature. The antifungal work consistently shows synergy rather than mere additivity: with caspofungin against Aspergillus fumigatus, Candida albicans, Candida auris and the intrinsically echinocandin-resistant Cryptococcus neoformans; with ibrexafungerp against Aspergillus fumigatus; and with azoles against Aspergillus and several Mucorales. The proposed mechanism — disruption of cell wall integrity signalling and membrane potential, removing the fungus's ability to compensate for cell wall damage — predicts synergy specifically with cell wall-targeting agents, which is what is observed. Against SARS-CoV-2 in cell culture, brilacidin showed synergistic antiviral activity with remdesivir, although the clinical trial that followed was negative. The theoretically plausible negative interactions have not been examined. Polycationic molecules can bind anionic drugs and biological polyanions, which is the mechanism behind several well-known incompatibilities — heparin being the classic example — and this would be worth characterising before any intravenous programme resumed. Nothing is known about combination with other membrane-active agents such as the polymyxins or amphotericin B, where additive membrane toxicity would be the concern rather than additive benefit.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions